S

SELLAS Life Sciences Group
D

SLS

1.17000
USD
-0.01
(-0.43%)
مغلق
حجم التداول
16,226
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
82,346,915
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALT
    -0.85500
    (-10.11%)
    7.60000 USD
    A
    ARWR
    -2.890
    (-13.49%)
    18.540 USD
    B
    BLCM
    -0.01620
    (-4.09%)
    0.36000 USD
    I
    IMRN
    0.08000
    (4.35%)
    1.92000 USD
    O
    ONTX
    0
    (0%)
    0.000000 USD
    P
    PAVM
    0.02000
    (1.79%)
    1.14000 USD
    T
    TNXP
    -0.00910
    (-6.53%)
    0.13030 USD
    V
    VCNX
    -0.56000
    (-15.05%)
    3.16000 USD
    المزيد
الأخبار

العنوان: SELLAS Life Sciences Group

القطاع: Healthcare
الصناعة: Biotechnology
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.